One study conducted in a tumor-burdened rat model of breast cancer indicated that tumor cell-derived HMGB1 can suppress a naturally acquired immune effector cell (CD8) or cytokine-dependent (IFN-γ-dependent) antitumor response, probably by enhancing tumor-associated Tregs to produce IL-10, which is necessary for immune suppression in vitro and in vivo [13]. Here, HMGB1 is linked to breast carcinoma.